Pharmacokinetics and selected pharmacodynamics of morphine and its active metabolites in horses after intravenous administration of four doses.

The research paper studies the impact and behavior (pharmacokinetics and pharmacodynamics) of different levels of administered morphine and its major metabolites in horses. The study adds value by exploring the effects of direct administration of identified metabolites.

Study Design and Execution

• The researchers worked with a group of ten horses to conduct this study.
• A single intravenous dose of morphine, in four possible levels (0.05, 0.1, 0.2, or 0.5 mg/kg), or a saline control, was given to the horses.
• The team collected blood samples from these horses for up to 72 hours post-administration and conducted rigorous LC/MS/MS analysis to detect morphine and its metabolites.
• Parameters such as step count, heart rate and rhythm, gastrointestinal borborygmi, fecal output, packed cell volume, and total protein were recorded to screen for any potential pharmacodynamic effects.

Research Findings

• Morphine-3 glucuronide (M3G) was primarily detected, in concentrations higher than morphine-6 glucuronide (M6G).
• The levels of M3G and M6G varied significantly across various dose groups.
• The researchers used a Noncompartmental Analysis (NCA) for the primary assessment of the morphine pharmacokinetics.
• The volume distribution at a steady-state and systemic clearance of morphine varied with the dosage, providing insights into how the drug, and its metabolites, are dispersed and cleared from the body.
• The research observed adverse effects, especially signs of reduced gastrointestinal motility and increased excitation in the central nervous system.
• There was a noticeable correlation between the increase in morphine dosage, increase in M3G concentrations, and the occurrence of adverse effects.

Implications of the Findings

• Through these findings, the research offers detailed insights into the pharmacokinetics and pharmacodynamic activity of morphine and its two major metabolites in horses, chiefly M3G and M6G.
• The study further recommends that purified M3G and M6G be directly administered to horses to refine understanding of the pharmacokinetics of morphine and metabolites and to assess the pharmacodynamics’ role of these metabolites better.
• Overall, the research lays the groundwork for improving pain management treatments for equine patients, considering the correlation between morphine dosage, metabolite levels and adverse effects.